J.P. Morgan Securities: The Vigil Neuroscience (VIGL.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $23.00.

J.P. Morgan Securities: The Vigil Neuroscience (VIGL.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $23.00.

Zhitong FinanceApr 19 01:40

JMP Securities Reiterates Market Outperform on Vigil Neuroscience, Maintains $23 Price Target

JMP Securities analyst Jason Butler reiterates Vigil Neuroscience (NASDAQ:VIGL) with a Market Outperform and maintains $23 price target.

BenzingaApr 19 01:39

Vigil Presents Key Findings From ILLUMINATE & IGNITE Studies In ALSP At The 2024 American Academy Of Neurology Annual Meeting

Vigil Neuroscience, Inc. (NASDAQ:VIGL) today announced the presentation of multiple oral and poster presentations on the Company's lead clinical candidate iluzanebart at the 2024 American Academy of Neurology (AAN) Annual Meeting.

BenzingaApr 18 04:21

Buy Rating Affirmed for Vigil Neuroscience on Promising Clinical Trials and Key Data Readouts

TipRanksMar 29 16:27

HC Wainwright & Co. Maintains Buy on Vigil Neuroscience, Maintains $24 Price Target

HC Wainwright & Co. analyst Andrew Fein maintains Vigil Neuroscience with a Buy and maintains $24 price target.

Analyst UpgradesMar 27 21:32

Vigil Neuroscience Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/27/2024 724.54% HC Wainwright & Co. $24 → $24 Maintains Buy 12/19/2023 37.42% Morgan Stanley $13 → $4 D

BenzingaMar 27 21:22